With Eli Lilly's diabetes and obesity products Mounjaro and Zepbound booming in popularity, the drugmaker finds itself in a ...
Eli Lilly and Co. approved a program to buy back as much as $15 billion of its own shares amid rapid growth fueled in part by ...
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...
Eli Lilly and Company LLY announced that its board of directors approved a new $15 billion share buyback plan. The earlier $5 ...
Zepbound outperformed Wegovy for weight loss in a new clinical trial funded by Eli Lilly & Co., Zepbound's maker.
One particular healthcare stock has shown its ability to soar on good news -- and it's had plenty of it. This year the ...
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), AbbVie ...
Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 524.46% and ...
S&P 500, JPMorgan Chase & Co, Eli Lilly and Company, Novo Nordisk A/S Class B. Read Edison Group (Melanie Jenner)'s latest article on Investing.com UK.
The sales surge signals the chip maker’s continued momentum amid the artificial-intelligence boom, though investors weren't ...
Hope usually springs eternal for the S&P 500 this time of year. But analysts are already sounding specific warnings for next ...
Olson, a 19-year veteran of the mechanical contracting leader, takes over for Gus Simonds, now Executive Chair of the Board ...